<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412631</url>
  </required_header>
  <id_info>
    <org_study_id>15-005230</org_study_id>
    <secondary_id>1K23DA037299-01A1</secondary_id>
    <secondary_id>14-005682</secondary_id>
    <nct_id>NCT02412631</nct_id>
  </id_info>
  <brief_title>Addressing Post Cessation Weight Gain</brief_title>
  <official_title>Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some individuals smoke with the perception that smoking helps control body weight. Smokers&#xD;
      gain an average of as much as 10 pounds in the months following smoking abstinence, with&#xD;
      heavier and more-dependent smokers gaining more weight. T The Mayo Clinic Nicotine Research&#xD;
      Program will randomize 100 nondiabetic, overweight or obese adult smokers to active&#xD;
      lorcaserin or placebo for 24 weeks; all of the subjects will receive open-label varenicline&#xD;
      for 12 weeks. The purpose of this study is to assess the efficacy of a 24-week course of&#xD;
      lorcaserin for decreasing weight gain after stopping smoking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, placebo-controlled, parallel-group clinical trial. Nondiabetic,&#xD;
      overweight and obese adult smokers will be randomized to one of three arms:&#xD;
&#xD;
        -  lorcaserin for 24 weeks in combination with varenicline for 12 weeks;&#xD;
&#xD;
        -  placebo for 24 weeks in combination with varenicline for 12 weeks;&#xD;
&#xD;
      We will assess the following:&#xD;
&#xD;
        -  changes in weight and Weight Concern&#xD;
&#xD;
        -  7-day point-prevalence smoking abstinence weekly through week 24 and prolonged smoking&#xD;
           abstinence at 24 and 52 weeks. Subjects will have a target quit date 8 days after&#xD;
           starting medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lorcaserin removed from market&#xD;
  </why_stopped>
  <start_date type="Actual">June 15, 2016</start_date>
  <completion_date type="Actual">April 17, 2020</completion_date>
  <primary_completion_date type="Actual">April 17, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Cessation Weight Gain (kg)</measure>
    <time_frame>24 weeks</time_frame>
    <description>weight (kg) change from baseline to week 24 among subjects who meet criteria for prolonged smoking abstinence at week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>24 weeks</time_frame>
    <description>BMI change from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking Abstinence</measure>
    <time_frame>24 weeks</time_frame>
    <description>Lorcaserin combined with open label varenicline will be evaluated for improved smoking abstinence compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>24 weeks</time_frame>
    <description>Waist Circumference change from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Mass</measure>
    <time_frame>24 weeks</time_frame>
    <description>Body Fat difference from baseline to week 24.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Obesity</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Varenicline plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline plus lorcaserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorcaserin</intervention_name>
    <description>lorcaserin is an FDA-approved weight loss medication for overweight and obese patients</description>
    <arm_group_label>Varenicline plus lorcaserin</arm_group_label>
    <other_name>Belviq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Chantix is an FDA approved medication for smoking cessation</description>
    <arm_group_label>Varenicline plus lorcaserin</arm_group_label>
    <arm_group_label>Varenicline plus placebo</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for lorcaserin</description>
    <arm_group_label>Varenicline plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects will be considered for inclusion if they meet all of the following&#xD;
&#xD;
          1. ≥18 years and ≤65 years of age;&#xD;
&#xD;
          2. smoked ≥10 cigarettes/day for the past 6 months;&#xD;
&#xD;
          3. Body Mass Index of 27-39.9 kg/m2;&#xD;
&#xD;
          4. motivated to stop smoking;&#xD;
&#xD;
          5. weight concerned as shown with the Weight Concern Scale;&#xD;
&#xD;
          6. able to participate fully in all aspects of the study;&#xD;
&#xD;
          7. understand and signed the study informed consent.&#xD;
&#xD;
          8. Subject is in good health as determined by the clinical investigators.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be ineligible for participation if they have any of the following:&#xD;
&#xD;
          1. current nonspecific suicidal thoughts or a lifetime history of a suicidal attempt&#xD;
             (defined by the Columbia-Suicide Severity Rating Scale as a &quot;potentially&#xD;
             self-injurious act committed with at least some wish to die, as a result of act.&quot;);&#xD;
&#xD;
          2. current moderate or severe depression as assessed by a score of ≥16 on the Center for&#xD;
             Epidemiology Studies-Depression;&#xD;
&#xD;
          3. a lifetime history of psychosis, bipolar disorder or schizophrenia;&#xD;
&#xD;
          4. use of anti-psychotic medication within the past 30 days;&#xD;
&#xD;
          5. use of weight-loss medications within the past 30 days or current participation in a&#xD;
             program specifically designed to help with weight loss;&#xD;
&#xD;
          6. weight fluctuations of 20 pounds or more in the past 6 months (self-report);&#xD;
&#xD;
          7. use of any treatments for tobacco dependence within the past 30 days;&#xD;
&#xD;
          8. use of an investigational drug within the past 30 days;&#xD;
&#xD;
          9. recent history (past 3 months) of abuse of or dependence on a substance other than&#xD;
             tobacco. Including: heavy alcohol consumption (If male, drinking &gt; 4 alcoholic&#xD;
             beverages per day for past month and if female, drinking &gt; 3 alcoholic beverages per&#xD;
             day for past month); use of cocaine, heroin, club drugs (i.e.,&#xD;
             methylenedioxymethamphetamine(MDMA)/&quot;ecstasy&quot;), methamphetamine, or hallucinogens&#xD;
             (e.g., LSD) at any time during the past 3 months; and use of marijuana on a weekly&#xD;
             basis for the past 3 months&#xD;
&#xD;
         10. current use of triptans, monoamine oxidase inhibitors, selective serotonin reuptake&#xD;
             inhibitors (SSRI), selective serotonin-norepinephrine re-uptake inhibitors (SNRI),&#xD;
             dextromethorphan, tricyclic antidepressants (TCA), bupropion, lithium, tramadol,&#xD;
             tryptophan, and St. John's Wort, or any other medication known to involve the&#xD;
             serotonergic neurotransmitter system (see human subjects section);&#xD;
&#xD;
         11. uncontrolled hypertension (systolic &gt;160 mm Hg and/or diastolic &gt;100 mm Hg) documented&#xD;
             on 2 separate occasions;&#xD;
&#xD;
         12. current use of medications known to interact with varenicline or lorcaserin. These can&#xD;
             include benzodiazepines, narcotics, anti-epileptics;&#xD;
&#xD;
         13. another household member or relative participating in the study;&#xD;
&#xD;
         14. known diabetes;&#xD;
&#xD;
         15. a known allergy to varenicline or lorcaserin.&#xD;
&#xD;
         16. Women who are pregnant or lactating, or who are of childbearing potential and are&#xD;
             likely to become pregnant during the medication phase but are not willing to use a&#xD;
             reliable form of contraception, will also be excluded. Reliable forms of contraception&#xD;
             include oral contraception, diaphragm or condom (with spermicide), injections,&#xD;
             intrauterine device, surgical sterilization, and abstinence.&#xD;
&#xD;
         17. Has an unstable medical condition as determined by the physician investigator&#xD;
&#xD;
         18. Subject describes having a medical history of: a) unstable angina; b) myocardial&#xD;
             infarction within the past 3 months; c) coronary angioplasty or d) an untreated&#xD;
             cardiac dysrhythmia.&#xD;
&#xD;
         19. Subject currently has cancer [excluding non-melanoma skin cancer] not in remission&#xD;
&#xD;
         20. Known history of seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan T Hurt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <results_first_submitted>April 10, 2021</results_first_submitted>
  <results_first_submitted_qc>May 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2021</results_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ryan T. Hurt, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02412631/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place between June 16th, 2016 to January 22nd, 2020. Recruitment was in three phases: initial phone pre-screen, followed by a consent visit and study screen, and finally a randomization visit. All visits took place at a medical clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline Plus Placebo</title>
          <description>Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation&#xD;
Placebo: Placebo for lorcaserin</description>
        </group>
        <group group_id="P2">
          <title>Varenicline Plus Lorcaserin</title>
          <description>Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)&#xD;
lorcaserin: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early stop by FDA</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified reason</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline Plus Placebo</title>
          <description>Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation&#xD;
Placebo: Placebo for lorcaserin</description>
        </group>
        <group group_id="B2">
          <title>Varenicline Plus Lorcaserin</title>
          <description>Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)&#xD;
lorcaserin: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="9.05"/>
                    <measurement group_id="B2" value="43.4" spread="10.98"/>
                    <measurement group_id="B3" value="42.3" spread="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cigarettes per day</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.2" spread="5.59"/>
                    <measurement group_id="B2" value="17.9" spread="5.96"/>
                    <measurement group_id="B3" value="17.5" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.8" spread="15.46"/>
                    <measurement group_id="B2" value="93.4" spread="14.7"/>
                    <measurement group_id="B3" value="92.6" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post Cessation Weight Gain (kg)</title>
        <description>weight (kg) change from baseline to week 24 among subjects who meet criteria for prolonged smoking abstinence at week 24</description>
        <time_frame>24 weeks</time_frame>
        <population>Restricted to those who met criteria for prolonged abstinence at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline Plus Placebo</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation&#xD;
Placebo: Placebo for lorcaserin</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Plus Lorcaserin</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)&#xD;
lorcaserin: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Post Cessation Weight Gain (kg)</title>
          <description>weight (kg) change from baseline to week 24 among subjects who meet criteria for prolonged smoking abstinence at week 24</description>
          <population>Restricted to those who met criteria for prolonged abstinence at week 24.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="8.38"/>
                    <measurement group_id="O2" value="2.2" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BMI</title>
        <description>BMI change from baseline to week 24</description>
        <time_frame>24 weeks</time_frame>
        <population>Restricted to those who met criteria for prolonged abstinence at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline Plus Placebo</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation&#xD;
Placebo: Placebo for lorcaserin</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Plus Lorcaserin</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)&#xD;
lorcaserin: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>BMI</title>
          <description>BMI change from baseline to week 24</description>
          <population>Restricted to those who met criteria for prolonged abstinence at week 24.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.91"/>
                    <measurement group_id="O2" value="0.8" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Abstinence</title>
        <description>Lorcaserin combined with open label varenicline will be evaluated for improved smoking abstinence compared to placebo</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline Plus Placebo</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation&#xD;
Placebo: Placebo for lorcaserin</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Plus Lorcaserin</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)&#xD;
lorcaserin: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Abstinence</title>
          <description>Lorcaserin combined with open label varenicline will be evaluated for improved smoking abstinence compared to placebo</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>Waist Circumference change from baseline to week 24</description>
        <time_frame>24 weeks</time_frame>
        <population>Restricted to those who met criteria for prolonged abstinence at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline Plus Placebo</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation&#xD;
Placebo: Placebo for lorcaserin</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Plus Lorcaserin</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)&#xD;
lorcaserin: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>Waist Circumference change from baseline to week 24</description>
          <population>Restricted to those who met criteria for prolonged abstinence at week 24.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="7.60"/>
                    <measurement group_id="O2" value="-0.1" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fat Mass</title>
        <description>Body Fat difference from baseline to week 24.</description>
        <time_frame>24 weeks</time_frame>
        <population>Restricted to those who met criteria for prolonged abstinence at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline Plus Placebo</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation&#xD;
Placebo: Placebo for lorcaserin</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Plus Lorcaserin</title>
            <description>Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)&#xD;
lorcaserin: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Fat Mass</title>
          <description>Body Fat difference from baseline to week 24.</description>
          <population>Restricted to those who met criteria for prolonged abstinence at week 24.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="7.12"/>
                    <measurement group_id="O2" value="2.2" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) were collected throughout the 24 week study period.</time_frame>
      <desc>Reported AEs were included in this section.</desc>
      <group_list>
        <group group_id="E1">
          <title>Varenicline Plus Placebo</title>
          <description>Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation&#xD;
Placebo: Placebo for lorcaserin</description>
        </group>
        <group group_id="E2">
          <title>Varenicline Plus Lorcaserin</title>
          <description>Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)&#xD;
lorcaserin: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients&#xD;
Varenicline: Chantix is an FDA approved medication for smoking cessation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>GI</sub_title>
                <description>Includes upset stomach, abdominal pain, bloating, and diarrhea.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sleep disorders</sub_title>
                <description>Includes sleep disorders and vivid dreams</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Mood</sub_title>
                <description>Includes irritability and depression</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ryan Hurt</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>(507) 284-2511</phone>
      <email>gimresearchstudies@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

